ALX Oncology Holdings Inc Submits Form 144 Filing to SEC
In a recent SEC filing, ALX Oncology Holdings Inc (SEC CIK: 0001810182) submitted a Form 144 indicating the intention to sell restricted shares. Form 144 is required when insiders of a company, such as directors or executives, plan to sell their shares. This filing provides transparency to investors about potential selling activities by company insiders, which can impact the stock price.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company dedicated to developing therapies that target the CD47 checkpoint pathway for cancer treatment. The company’s innovative approach aims to harness the body’s immune system to combat cancer effectively. With a focus on developing novel drugs for difficult-to-treat cancers, ALX Oncology Holdings Inc continues to advance its pipeline of promising therapies.
Form 144 filed by ALX Oncology Holdings Inc signifies a potential upcoming sale of restricted shares by insiders of the company. Investors and analysts will closely monitor any developments related to this filing to gauge the impact on the company’s stock performance. For more information about ALX Oncology Holdings Inc and its groundbreaking work in immuno-oncology, visit their official website ALX Oncology Holdings Inc.
Read More:
ALX Oncology Holdings Inc Submits Form 144 Filing to SEC
